{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:31:59Z","timestamp":1793914319688,"version":"4.8.0"},"reference-count":93,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013142","name":"Key Research and Development Project of Hainan Province","doi-asserted-by":"publisher","award":["ZDYF2021SHFZ234"],"award-info":[{"award-number":["ZDYF2021SHFZ234"]}],"id":[{"id":"10.13039\/501100013142","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013142","name":"Key Research and Development Project of Hainan Province","doi-asserted-by":"publisher","award":["ZDYF2024SHFZ102"],"award-info":[{"award-number":["ZDYF2024SHFZ102"]}],"id":[{"id":"10.13039\/501100013142","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81201803"],"award-info":[{"award-number":["81201803"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["NHXX-WJW-2023014"],"award-info":[{"award-number":["NHXX-WJW-2023014"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004761","name":"Natural Science Foundation of Hainan Province","doi-asserted-by":"publisher","award":["820QN403"],"award-info":[{"award-number":["820QN403"]}],"id":[{"id":"10.13039\/501100004761","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004761","name":"Natural Science Foundation of Hainan Province","doi-asserted-by":"publisher","award":["819QN364"],"award-info":[{"award-number":["819QN364"]}],"id":[{"id":"10.13039\/501100004761","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008111","name":"Hainan Provincial Department of Science and Technology","doi-asserted-by":"publisher","award":["YSGZZ2024001"],"award-info":[{"award-number":["YSGZZ2024001"]}],"id":[{"id":"10.13039\/501100008111","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008111","name":"Hainan Provincial Department of Science and Technology","doi-asserted-by":"publisher","award":["N0.YSPTZX202501"],"award-info":[{"award-number":["N0.YSPTZX202501"]}],"id":[{"id":"10.13039\/501100008111","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010834","name":"Education Department of Hainan Province","doi-asserted-by":"publisher","award":["Hnky2022-34"],"award-info":[{"award-number":["Hnky2022-34"]}],"id":[{"id":"10.13039\/501100010834","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007935","name":"Hainan Medical University","doi-asserted-by":"publisher","award":["XSTS2025038"],"award-info":[{"award-number":["XSTS2025038"]}],"id":[{"id":"10.13039\/501100007935","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007935","name":"Hainan Medical University","doi-asserted-by":"publisher","award":["XSTS2025004"],"award-info":[{"award-number":["XSTS2025004"]}],"id":[{"id":"10.13039\/501100007935","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007935","name":"Hainan Medical University","doi-asserted-by":"publisher","award":["XSTS2025111"],"award-info":[{"award-number":["XSTS2025111"]}],"id":[{"id":"10.13039\/501100007935","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.tranon.2025.102660","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T07:08:17Z","timestamp":1767683297000},"page":"102660","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Adaptive therapy for perioperative non\u2013small cell lung cancer: strategies guided by dynamic minimal residual disease adjustment"],"prefix":"10.1016","volume":"64","author":[{"given":"Li-Jin","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Li","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Cen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Sen","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bai-Cheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiong-Wen","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Feng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8723-7652","authenticated-orcid":false,"given":"Yue-Can","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Jun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.tranon.2025.102660_bib0001","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.tranon.2025.102660_bib0002","first-page":"47","article-title":"Cancer incidence and mortality in China, 2022","volume":"4","author":"Han","year":"2024","journal-title":"J Natl Cancer Cent"},{"key":"10.1016\/j.tranon.2025.102660_bib0003","first-page":"46","article-title":"Five-year survival and prognostic factors according to histology in 6101 non-small-cell lung cancer patients","volume":"77","author":"Molinier","year":"2020","journal-title":"Respir Med Res"},{"issue":"2","key":"10.1016\/j.tranon.2025.102660_bib0004","first-page":"189","article-title":"Lung cancer: biology and treatment options","volume":"1856","author":"Lemjabbar-Alaoui","year":"2015","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"10.1016\/j.tranon.2025.102660_bib0005","first-page":"7","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin."},{"issue":"21","key":"10.1016\/j.tranon.2025.102660_bib0006","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/jnci\/djs441","article-title":"Combining molecular markers with the TNM staging system to improve prognostication in stage II and III colon cancer: are we ready yet?","volume":"104","author":"Sinicrope","year":"2012","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"10.1016\/j.tranon.2025.102660_bib0007","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.17062","article-title":"Comparison of Conventional TNM and Novel TNMB Staging Systems for Non-Small Cell Lung Cancer","volume":"2","author":"Haro","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.tranon.2025.102660_bib0008","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3389\/fonc.2019.00771","article-title":"A Proposal to Reflect Survival Difference and Modify the Staging System for Lung Adenocarcinoma and Squamous Cell Carcinoma: based on the Machine Learning","volume":"9","author":"Li","year":"2019","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.tranon.2025.102660_bib0009","first-page":"1390","article-title":"Carcinoembryonic antigen and carbohydrate antigen 19-9 serum levels in non-small cell lung cancer","volume":"22","author":"Tsoukalas","year":"2017","journal-title":"J buon"},{"issue":"11","key":"10.1016\/j.tranon.2025.102660_bib0010","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1200\/JCO.1995.13.11.2769","article-title":"Low specificity of cytokeratin 19 reverse transcriptase-polymerase chain reaction analyses for detection of hematogenous lung cancer dissemination","volume":"13","author":"Krismann","year":"1995","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.tranon.2025.102660_bib0011","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1038\/s41375-024-02252-4","article-title":"Measurable residual disease (MRD)-testing in haematological and solid cancers","volume":"38","author":"Chen","year":"2024","journal-title":"Leukemia"},{"issue":"26","key":"10.1016\/j.tranon.2025.102660_bib0012","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2025.102660_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2023.1200124","article-title":"Clinical application of liquid biopsy based on circulating tumor DNA in non-small cell lung cancer","volume":"14","author":"Xin","year":"2023","journal-title":"Front Physiol"},{"issue":"1","key":"10.1016\/j.tranon.2025.102660_bib0014","article-title":"Monitoring of Measurable Residual Disease in Multiple Myeloma by Multiparametric Flow Cytometry","volume":"90","author":"Soh","year":"2019","journal-title":"Curr Protoc Cytom"},{"issue":"10","key":"10.1016\/j.tranon.2025.102660_bib0015","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/j.ccell.2023.09.007","article-title":"Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non-small cell lung cancer patients","volume":"41","author":"Pan","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.tranon.2025.102660_bib0016","first-page":"47","article-title":"Detection of minimal residual disease in acute leukemia by immunological marker analysis and polymerase chain reaction","volume":"6 Suppl 1","author":"van Dongen","year":"1992","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.tranon.2025.102660_bib0017","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa1213261","article-title":"Analysis of circulating tumor DNA to monitor metastatic breast cancer","volume":"368","author":"Dawson","year":"2013","journal-title":"N Engl J Med"},{"issue":"466","key":"10.1016\/j.tranon.2025.102660_bib0018","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat4921","article-title":"Enhanced detection of circulating tumor DNA by fragment size analysis","volume":"10","author":"Mouliere","year":"2018","journal-title":"Sci Transl Med"},{"issue":"23","key":"10.1016\/j.tranon.2025.102660_bib0019","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242317073","article-title":"Circulating Tumor DNA Is a Variant of Liquid Biopsy with Predictive and Prognostic Clinical Value in Breast Cancer Patients","volume":"24","author":"Zavarykina","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/j.tranon.2025.102660_bib0020","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1111\/cas.14926","article-title":"CIRCULATE-Japan: circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer","volume":"112","author":"Taniguchi","year":"2021","journal-title":"Cancer Sci"},{"issue":"11","key":"10.1016\/j.tranon.2025.102660_bib0021","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1038\/s41591-024-03254-6","article-title":"ctDNA-based molecular residual disease and survival in resectable colorectal cancer","volume":"30","author":"Nakamura","year":"2024","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.tranon.2025.102660_bib0022","doi-asserted-by":"crossref","first-page":"6123","DOI":"10.1038\/s41467-021-26308-6","article-title":"Calibration-free NGS quantitation of mutations below 0.01% VAF","volume":"12","author":"Dai","year":"2021","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.tranon.2025.102660_bib0023","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1038\/s44321-024-00115-0","article-title":"Ultra-sensitive molecular residual disease detection through whole genome sequencing with single-read error correction","volume":"16","author":"Li","year":"2024","journal-title":"EMBO Mol Med"},{"issue":"24","key":"10.1016\/j.tranon.2025.102660_bib0024","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","article-title":"Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer","volume":"386","author":"Tie","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.tranon.2025.102660_bib0025","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1038\/s41591-025-03579-w","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial","volume":"31","author":"Tie","year":"2025","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.tranon.2025.102660_bib0026","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1038\/s41591-025-03577-y","article-title":"Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer","volume":"31","author":"Herbst","year":"2025","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.tranon.2025.102660_bib0027","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1158\/2159-8290.CD-17-0716","article-title":"Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling","volume":"7","author":"Chaudhuri","year":"2017","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.tranon.2025.102660_bib0028","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13045-023-01436-2","article-title":"Emerging evidence and treatment paradigm of non-small cell lung cancer","volume":"16","author":"Liu","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"4","key":"10.1016\/j.tranon.2025.102660_bib0029","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.pccm.2023.04.001","article-title":"Circulating tumor DNA (ctDNA)-based minimal residual disease in non-small cell lung cancer","volume":"1","author":"Tang","year":"2023","journal-title":"Chin Med J Pulm Crit Care Med"},{"issue":"21","key":"10.1016\/j.tranon.2025.102660_bib0030","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1200\/JCO.2007.13.9030","article-title":"Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group","volume":"26","author":"Pignon","year":"2008","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.tranon.2025.102660_bib0031","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/S1470-2045(17)30691-5","article-title":"Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial","volume":"18","author":"Wakelee","year":"2017","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.tranon.2025.102660_bib0032","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/j.chest.2023.11.042","article-title":"Recurrence-Free Survival in Patients With Surgically Resected Non-Small Cell Lung Cancer: a Systematic Literature Review and Meta-Analysis","volume":"165","author":"Rajaram","year":"2024","journal-title":"Chest"},{"issue":"15","key":"10.1016\/j.tranon.2025.102660_bib0033","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1158\/1078-0432.CCR-21-3044","article-title":"Perioperative ctDNA-Based Molecular Residual Disease Detection for Non-Small Cell Lung Cancer: a Prospective Multicenter Cohort Study (LUNGCA-1)","volume":"28","author":"Xia","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"7655","key":"10.1016\/j.tranon.2025.102660_bib0034","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature22364","article-title":"Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution","volume":"545","author":"Abbosh","year":"2017","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.tranon.2025.102660_bib0035","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1002\/cncr.35263","article-title":"Detection of circulating tumor DNA with ultradeep sequencing of plasma cell-free DNA for monitoring minimal residual disease and early detection of recurrence in early-stage lung cancer","volume":"130","author":"Tan","year":"2024","journal-title":"Cancer"},{"issue":"21","key":"10.1016\/j.tranon.2025.102660_bib0036","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.tranon.2025.102660_bib0037","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S1470-2045(20)30453-8","article-title":"Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial","volume":"21","author":"Provencio","year":"2020","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.tranon.2025.102660_bib0038","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s43018-019-0011-0","article-title":"Circulating Tumor DNA Dynamics Predict Benefit from Consolidation Immunotherapy in Locally Advanced Non-Small Cell Lung Cancer","volume":"1","author":"Moding","year":"2020","journal-title":"Nat Cancer"},{"issue":"18","key":"10.1016\/j.tranon.2025.102660_bib0039","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.tranon.2025.102660_bib0040","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3892\/ol.2011.420","article-title":"Histologic coagulative tumour necrosis as a prognostic indicator of aggressiveness in renal, lung, thyroid and colorectal carcinomas: a brief review","volume":"3","author":"Caruso","year":"2012","journal-title":"Oncol Lett"},{"issue":"10","key":"10.1016\/j.tranon.2025.102660_bib0041","first-page":"4073","article-title":"Prognostic significance of p27KIP1 protein and ki-67 growth fraction in non-small cell lung cancers","volume":"6","author":"Hommura","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.tranon.2025.102660_bib0042","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nm.3519","article-title":"An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage","volume":"20","author":"Newman","year":"2014","journal-title":"Nat Med"},{"issue":"10308","key":"10.1016\/j.tranon.2025.102660_bib0043","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.tranon.2025.102660_bib0044","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","article-title":"Perioperative Nivolumab in Resectable Lung Cancer","volume":"390","author":"Cascone","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.tranon.2025.102660_bib0045","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1080\/21655979.2021.1890382","article-title":"Targeted next-generation sequencing for cancer-associated gene mutation and copy number detection in 206 patients with non-small-cell lung cancer","volume":"12","author":"Zheng","year":"2021","journal-title":"Bioengineered"},{"issue":"3","key":"10.1016\/j.tranon.2025.102660_bib0046","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.3892\/or.2015.4533","article-title":"Complex analysis of the p53 tumor suppressor in lung carcinoma","volume":"35","author":"Smardova","year":"2016","journal-title":"Oncol Rep"},{"issue":"2","key":"10.1016\/j.tranon.2025.102660_bib0047","article-title":"PIK3CA mutations frequently coexist with EGFR\/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR\/KRAS wildtype subgroup","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS One"},{"issue":"7957","key":"10.1016\/j.tranon.2025.102660_bib0048","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/s41586-023-05729-x","article-title":"The evolution of non-small cell lung cancer metastases in TRACERx","volume":"616","author":"Al Bakir","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.tranon.2025.102660_bib0049","article-title":"Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer","volume":"6","author":"Sheng","year":"2016","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.tranon.2025.102660_bib0050","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1073\/pnas.1819473116","article-title":"Reactive oxygen species modulate macrophage immunosuppressive phenotype through the up-regulation of PD-L1","volume":"116","author":"Roux","year":"2019","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"4","key":"10.1016\/j.tranon.2025.102660_bib0051","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/1878-0261.12032","article-title":"Chemotherapy induces tumor immune evasion by upregulation of programmed cell death ligand 1 expression in bone marrow stromal cells","volume":"11","author":"Yang","year":"2017","journal-title":"Mol Oncol"},{"issue":"6230","key":"10.1016\/j.tranon.2025.102660_bib0052","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"issue":"6230","key":"10.1016\/j.tranon.2025.102660_bib0053","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.tranon.2025.102660_bib0054","article-title":"Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.tranon.2025.102660_bib0055","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12092592","article-title":"Heat Shock Proteins and PD-1\/PD-L1 as Potential Therapeutic Targets in Myeloproliferative Neoplasms","volume":"12","author":"De Almeida","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.tranon.2025.102660_bib0056","first-page":"8111","article-title":"Combined inhibition of JAK1,2\/Stat3\u2011PD\u2011L1 signaling pathway suppresses the immune escape of castration\u2011resistant prostate cancer to NK cells in hypoxia","volume":"17","author":"Xu","year":"2018","journal-title":"Mol Med Rep"},{"issue":"18","key":"10.1016\/j.tranon.2025.102660_bib0057","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.tranon.2025.102660_bib0058","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1001\/jamaoncol.2024.1779","article-title":"Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced Non-Small Cell Lung Cancer: a Nonrandomized Controlled Trial","volume":"10","author":"Dong","year":"2024","journal-title":"JAMA Oncol"},{"issue":"8","key":"10.1016\/j.tranon.2025.102660_bib0059","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1001\/jamaoncol.2023.1891","article-title":"Association Between Duration of Immunotherapy and Overall Survival in Advanced Non-Small Cell Lung Cancer","volume":"9","author":"Sun","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.tranon.2025.102660_bib0060","article-title":"Impact of pembrolizumab treatment duration on overall survival and prognostic factors in advanced non-small cell lung cancer: a nationwide retrospective cohort study","volume":"43","author":"Rousseau","year":"2024","journal-title":"Lancet Reg Health Eur"},{"issue":"7","key":"10.1016\/j.tranon.2025.102660_bib0061","first-page":"2049","article-title":"Role of minimal residual disease assessment in multiple myeloma","volume":"109","author":"Szalat","year":"2024","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.tranon.2025.102660_bib0062","doi-asserted-by":"crossref","first-page":"e867","DOI":"10.1016\/S2352-3026(23)00240-5","article-title":"MRD-guided treatment cessation in multiple myeloma","volume":"10","author":"Derman","year":"2023","journal-title":"Lancet Haematol"},{"issue":"22","key":"10.1016\/j.tranon.2025.102660_bib0063","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.tranon.2025.102660_bib0064","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.ccell.2021.07.005","article-title":"Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): a multicenter phase 3 study","volume":"39","author":"Zhou","year":"2021","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.tranon.2025.102660_bib0065","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1056\/NEJMoa2215530","article-title":"Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer","volume":"389","author":"Provencio","year":"2023","journal-title":"N Engl J Med."},{"issue":"21","key":"10.1016\/j.tranon.2025.102660_bib0066","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.tranon.2025.102660_bib0067","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1038\/s41591-023-02598-9","article-title":"ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results","volume":"29","author":"Anagnostou","year":"2023","journal-title":"Nat Med"},{"issue":"20","key":"10.1016\/j.tranon.2025.102660_bib0068","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.tranon.2025.102660_bib0069","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1158\/2159-8290.CD-21-1486","article-title":"Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non-Small Cell Lung Cancer","volume":"12","author":"Zhang","year":"2022","journal-title":"Cancer Discov"},{"issue":"7","key":"10.1016\/j.tranon.2025.102660_bib0070","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1158\/1078-0432.CCR-24-2909","article-title":"Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non-Small Cell Lung Cancer","volume":"31","author":"Zhang","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"7957","key":"10.1016\/j.tranon.2025.102660_bib0071","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41586-023-05776-4","article-title":"Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA","volume":"616","author":"Abbosh","year":"2023","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.tranon.2025.102660_bib0072","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1158\/1078-0432.CCR-19-3418","article-title":"Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC","volume":"26","author":"Hellmann","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.tranon.2025.102660_bib0073","doi-asserted-by":"crossref","first-page":"e890","DOI":"10.1016\/S2352-3026(23)00236-3","article-title":"Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial","volume":"10","author":"Costa","year":"2023","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.tranon.2025.102660_bib0074","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cllc.2023.09.008","article-title":"Adjuvant Therapy-Free Strategy for Stage IB to IIIA Non-Small-Cell Lung Cancer Patients After Radical Resection Based on Longitudinal Undetectable Molecular Residual Disease: prospective, Multicenter, Single-Arm Study (CTONG 2201)","volume":"25","author":"Zhang","year":"2024","journal-title":"Clin Lung Cancer"},{"issue":"12","key":"10.1016\/j.tranon.2025.102660_bib0075","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004952","article-title":"Short-term dynamics of circulating tumor DNA predicting efficacy of sintilimab plus docetaxel in second-line treatment of advanced NSCLC: biomarker analysis from a single-arm, phase 2 trial","volume":"10","author":"Han","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.tranon.2025.102660_bib0076","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","article-title":"The American Joint Committee on Cancer: the7th editionof the AJCC cancer staging manual and the future of TNM","volume":"17","author":"Edge","year":"2010","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"10.1016\/j.tranon.2025.102660_bib0077","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.trecan.2024.04.004","article-title":"Implementing circulating tumor DNA as a prognostic biomarker in resectable non-small cell lung cancer","volume":"10","author":"Abbosh","year":"2024","journal-title":"Trends Cancer"},{"issue":"10","key":"10.1016\/j.tranon.2025.102660_bib0078","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/j.ccell.2023.08.010","article-title":"Individualized tumor-informed circulating tumor DNA analysis for postoperative monitoring of non-small cell lung cancer","volume":"41","author":"Chen","year":"2023","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.tranon.2025.102660_bib0079","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.jtho.2019.03.015","article-title":"Incorporation of a Molecular Prognostic Classifier Improves Conventional Non-Small Cell Lung Cancer Staging","volume":"14","author":"Kratz","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.tranon.2025.102660_bib0080","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1141108","article-title":"Mycosis fungoides and S\u00e9zary syndrome: clinical presentation, diagnosis, staging, and therapeutic management","volume":"13","author":"Miyashiro","year":"2023","journal-title":"Front Oncol"},{"issue":"129","key":"10.1016\/j.tranon.2025.102660_bib0081","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1183\/09059180.00003913","article-title":"Surgery for nonsmall cell lung cancer","volume":"22","author":"Lang-Lazdunski","year":"2013","journal-title":"Eur Respir Rev"},{"issue":"4","key":"10.1016\/j.tranon.2025.102660_bib0082","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1001\/jamaoncol.2015.1241","article-title":"JAMA Oncology Patient Page. Neoadjuvant Therapy","volume":"1","author":"West","year":"2015","journal-title":"JAMA Oncol"},{"issue":"16","key":"10.1016\/j.tranon.2025.102660_bib0083","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23169006","article-title":"Making the Rounds: exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer","volume":"23","author":"Shields","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.tranon.2025.102660_bib0084","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s12916-023-02954-z","article-title":"Individualized dynamic methylation-based analysis of cell-free DNA in postoperative monitoring of lung cancer","volume":"21","author":"Chen","year":"2023","journal-title":"BMC Med"},{"issue":"1","key":"10.1016\/j.tranon.2025.102660_bib0085","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s12916-023-02849-z","article-title":"Accuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer: a meta-analysis","volume":"21","author":"Zhong","year":"2023","journal-title":"BMC Med"},{"issue":"302","key":"10.1016\/j.tranon.2025.102660_bib0086","doi-asserted-by":"crossref","first-page":"302ra133","DOI":"10.1126\/scitranslmed.aab0021","article-title":"Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer","volume":"7","author":"Garcia-Murillas","year":"2015","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.tranon.2025.102660_bib0087","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1124\/pr.57.2.4","article-title":"The blood-brain barrier\/neurovascular unit in health and disease","volume":"57","author":"Hawkins","year":"2005","journal-title":"Pharmacol Rev"},{"issue":"19","key":"10.1016\/j.tranon.2025.102660_bib0088","doi-asserted-by":"crossref","first-page":"5419","DOI":"10.1158\/0008-5472.CAN-17-0885","article-title":"Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation Sequencing","volume":"77","author":"Schwaederle","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.tranon.2025.102660_bib0089","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1486310","article-title":"Artificial intelligence in lung cancer: current applications, future perspectives, and challenges","volume":"14","author":"Huang","year":"2024","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.tranon.2025.102660_bib0090","first-page":"203","article-title":"The potential role of minimal\/molecular residual disease in colorectal cancer: curative surgery, radiotherapy and beyond","volume":"3","author":"Xu","year":"2023","journal-title":"J Natl Cancer Cent"},{"key":"10.1016\/j.tranon.2025.102660_bib0091","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2023.1172108","article-title":"Minimal residual disease (MRD) detection in solid tumors using circulating tumor DNA: a systematic review","volume":"14","author":"Zhu","year":"2023","journal-title":"Front Genet"},{"issue":"5","key":"10.1016\/j.tranon.2025.102660_bib0092","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.molmed.2020.12.011","article-title":"Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA","volume":"27","author":"Luo","year":"2021","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.tranon.2025.102660_bib0093","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.544680","article-title":"Genomic Profiling of Circulating Tumor DNA From Cerebrospinal Fluid to Guide Clinical Decision Making for Patients With Primary and Metastatic Brain Tumors","volume":"11","author":"Ramkissoon","year":"2020","journal-title":"Front Neurol."}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523325003912?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523325003912?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:55:28Z","timestamp":1781178928000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523325003912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":93,"alternative-id":["S1936523325003912"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2025.102660","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adaptive therapy for perioperative non\u2013small cell lung cancer: strategies guided by dynamic minimal residual disease adjustment","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2025.102660","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102660"}}